Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Humans
Myocarditis
Cardio-oncology
Acid-alpha-glucosidase
Immune checkpoint inhibitors
Adjudication
Anti-synthetase syndrome
Polymyositis
Adeno-associated vector
Muscle
Anti-IgE IgG
Agalsidase
Active
Middle Aged
Biomarqueurs
AAV antibody
Autoimmune diseases
Gene therapy
AAV
Lysosomal storage diseases
Anti-Mi2
DM
AAV humoral immunity
COVID-19
Skeletal muscle
Dermatomyositis
Anémie hémolytique
Antiphospholipid syndrome
Assisted communication devices
Animals
Myopathy
AAV vectors
Auto-antibodies
Female
Prognosis
Aldosterone
Anti-MDA5 autoantibodies
Data integration
Anti-agalsidase antibodies
Autoantibody
Myositis
Amyotrophy
Adolescence
Antisynthetase syndrome
Outcome measures
Adverse drug reactions
Inflammation
Mass cytometry
Anti-drug antibodies
Machine learning
Inflammatory myopathy
Auto-immunité
Aldostérone
Fabry disease
Pharmacology
Acute Kidney Injury/epidemiology/etiology
Male
Inborn errors of metabolism
Inclusion body myositis
Idiopathic inflammatory myopathies
AAV vector
Anti‐mitochondrial antibodies
Interstitial lung disease
IBM
Analyses multidimensionnelles
Anticorps anti-agalsidase
Biopsy
Autoantibodies
Multidisciplinarity
Dependovirus/genetics/immunology
Anti-interleukin-6
Interferon
Bioelectrical impedance analysis
Amyotrophic lateral sclerosis
Immunotherapy
Sphingosine-1-phosphate
Biomarkers
Antisynthetase
Adeno-associated virus
Adult
Cytokines
Antibodies
Cancer
B-lymphocyte
Anticorps spécifique des myosites
Adeno-associated virus vector
Biomarker
Antibody responses
Auto‐antibodies
Antisynthétase
IMNM
Abnormal movement
B cell homeostasis
Deep immune profiling
Myositis and muscle disease
Aged
Case reports
Arthritis
Systems biology
Autoimmunity